Development of technologies for sustained drug delivery is a topic of great interest among retina specialists considering the number of chronic conditions that are managed with repeated intravitreal injections.
Results from 3 years of follow-up in the phase III trial investigating treatment with adeno-associated viral vector delivery of human RPE65 (voretigene neparvovec, Spark Therapeutics) show this gene therapy has an acceptable safety profile.
The fluocinolone acetonide 0.2 mcg/day implant (Iluvien, Alimera Sciences) offers an additional option for treating diabetic macular edema that reduces the need for subsequent therapy with anti-vascular endothelial growth factor or steroid treatment.
NEW ORLEANS – There’s no place quite like Retina Subspecialty Day for retina specialists to hear about data released throughout the year — both positive and negative results this year, said David Brown, MD (Houston).
Pregnant patients require special care and surveillance when retinal diseases are present.
Bausch + Lomb has introduced an ultrasonic-powered hypersonic vitrectomy system that is driven exclusively by the company’s Stellaris Elite Vision Enhancement System. It has a novel mechanism of action and is expected to offer advantages compared with guillotine vitrectors, according to the company.
ALG-1001 is an integrin receptor inhibitor that acts to stabilize the retina’s response to diabetes-related hypoxic and oxidative stress, mitigating production of a host of molecules involved in the development of diabetic macular edema.
Take-Home Message: A pearl for preventing endophthalmitis following intravitreal injections: avoid eyelid contact with the injection site after the last application of povidone iodine.
The visual outcomes after anti-VEGF therapy administered to treat diabetic macular edema in the “real world” do not achieve those reported in randomized clinical trials. Eyes with better baseline visual acuity are disproportionately affected.